Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More
SP Tulsian of sptulsian.com feels that Indraprastha Medical Corporation can move to about Rs 40 maybe in six months. "It has 700 beds hospital in Delhi, which is one of the largest hospitals in the country and they have the capacity to expand to 1,000 beds as well," he adds.
SP Tulsian of sptulsian.com asks traders to keep a view of about six months and look for a target of Rs 500 on Torrent Pharmaceuticals. He expects Indraprastha Medical Corporation, which is now ruling at around Rs 33, to move to Rs 40 maybe in six months or so.
Indraprastha Medical can move to Rs 50 in next twelve months, says SP Tulsian, sptulsian.com.
Hold Indraprastha Medical Corporation for long term, says Aashish Tater, Head of Research, Fort Share Broking.